Evidence map›Paper›PMID 40526090›Full record

ArticleOncotarget2025

Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment.

Alberto Hernando-Calvo, Razelle Kurzrock, Nadia Saoudi Gonzalez, Shai Magidi, Catherine Bresson, Fanny Wunder, Giulia Pretelli, Agatha Martin Casado, Wafik S El-Deiry

Abstract readCase Reports
In one paragraph

Article in Oncotarget, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alberto Hernando-Calvo *Vall d'Hebron University Hospital, Barcelona, Spain.
Razelle Kurzrock *Worldwide Innovative Network (WIN) Association - WIN Consortium, Chevilly-Larue 94550, France.
Nadia Saoudi GonzalezVall d'Hebron University Hospital, Barcelona, Spain.
Shai MagidiWorldwide Innovative Network (WIN) Association - WIN Consortium, Chevilly-Larue 94550, France.
Catherine BressonWorldwide Innovative Network (WIN) Association - WIN Consortium, Chevilly-Larue 94550, France.
Fanny WunderWorldwide Innovative Network (WIN) Association - WIN Consortium, Chevilly-Larue 94550, France.
Giulia PretelliVall d'Hebron University Hospital, Barcelona, Spain.
Agatha Martin CasadoVall d'Hebron Institute of Oncology, Barcelona, Spain.
Wafik S El-Deiry *Worldwide Innovative Network (WIN) Association - WIN Consortium, Chevilly-Larue 94550, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heavily pretreated metastatic colorectal cancer (mCRC) poses significant therapeutic challenges. Advances in molecular profiling enables personalized strategies. We present a 62-year-old male with mCRC harboring

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsBiomarkers, TumorCamptothecinFluorouracilHumansLeucovorinMaleMiddle AgedMutationNeoplasm MetastasisBiomarkers, TumorCamptothecinFluorouracilLeucovorincancercancer managementcolorectal carcinomamolecular tumor boardprecision oncology

Identifiers

PMID40526090
PMCPMC12175699

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.